North Tide Capital’s Aegerion Pharmaceuticals AEGR Stock Holding History

North Tide Capital’s Portfolio AEGR Stock Details AEGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-919,414	Closed	-$12.5M	–	17
2015 Q3	$12.5M	Sell	919,414 -80,586	-8%	-$1.43M	1.09%	16
2015 Q2	$19M	Buy	1,000,000 +700,000	+233%	+$15.2M	1.37%	20
2015 Q1	$7.85M	Buy	300,000 +100,000	+50%	+$2.54M	0.59%	20
2014 Q4	$4.19M	Buy	+200,000	New	+$5.04M	0.28%	25

Other funds holding AEGR

ACM

Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

North Tide Capital's AEGR Position: Q4 2015 in Review

North Tide Capital sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2015, closing a stake of 919,414 shares — an estimated $12.5M sold.

North Tide Capital first reported a position in AEGR in Q4 2014 and held it in 4 quarters. The position peaked at $19M in Q2 2015. 109 funds tracked by Wall St. Rank hold AEGR as of Q4 2015.

North Tide Capital reported no remaining Aegerion Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
North Tide Capital sold 919,414 Aegerion Pharmaceuticals shares in Q4 2015, an estimated $12.5M.
North Tide Capital first reported a position in Aegerion Pharmaceuticals in Q4 2014 and held it in 4 quarters.
North Tide Capital's Aegerion Pharmaceuticals position peaked at $19M in Q2 2015.
109 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2015.

Based on North Tide Capital's 13F filing for Q4 2015, filed 16 Feb 2016.